FDA's Latest Guide: Drug Safety Reports, Now with Timely Clarity
Published Date: 12/16/2025
Notice
Summary
The FDA just released final rules to help drug study sponsors keep safety reports clear and on time for new drug and bioequivalence studies. If you’re running these studies, you’ll need to follow these updated safety reporting steps starting now to avoid delays or extra costs. This guidance makes safety checks easier and keeps everyone on the same page for safer medicines.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Final guidance for IND safety reporting
If you run investigational new drug (IND) studies or IND‑exempt bioavailability/bioequivalence (BA/BE) studies, FDA issued a final guidance on December 16, 2025 with recommendations to help sponsors and sponsor‑investigators comply with expedited IND safety reporting (see 21 CFR 312.32 and 21 CFR 320.31(d)(3)). The guidance finalizes the June 28, 2021 draft and consolidates prior guidance to clarify sponsors' safety reporting responsibilities.
Revised aggregate analyses and rare disease guidance
The final guidance revises recommended approaches for aggregate analyses to reduce the need for unblinding when evaluating safety data. It also adds additional considerations specifically for small programs and rare disease studies.
Updated electronic submission information
The guidance provides updated information on electronic submission of IND safety reports, including references to electronic submission pathways such as the Electronic Submission Gateway and the Safety Reporting Portal. Related collections of information cited in the notice are approved under OMB control number 0910-0291.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-22869 — Investigator Responsibilities-Safety Reporting for Investigational Drugs and Devices; Guidance for Investigators, Industry, and Institutional Review Boards; Availability
The FDA just released final guidance to help researchers safely report problems with new drugs and devices during studies. This update affects clinical investigators, companies, and review boards by clarifying what safety info must be shared and when. The guidance is effective now, aiming to keep everyone on the same page without adding extra costs or delays.
Next: 2025-22871 — Sunshine Act Meetings
The National Credit Union Administration is holding an open meeting on December 18, 2025, to talk about the Share Insurance Fund and the 2026-2027 budget. Credit unions and the public get a clear look at how money is managed and planned. This meeting keeps things transparent and on track for the coming years without any new costs announced.